Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5327581 | 0.85 | HRH1 (0.44) | HRH1 | |
| SCHEMBL13993925 | 0.82 | KDM4E (0.42) | HSD17B10GLAKDM4ETSHRALOX15 | |
| SCHEMBL6226343 | 0.81 | CYP2C19 (0.40) | ALDH1A1SMN1; SMN2MAPTKMT2AHRH1 | |
| Lithium Ion SCHEMBL31567197 | 0.81 | KDM4E (0.41) | HSD17B10GLAKDM4ETSHRALOX15 | |
| SCHEMBL16080789 | 0.79 | SMN1; SMN2 (0.42) | HSD17B10GLAKDM4ETSHRALOX15 | |
| SCHEMBL19413400 | 0.79 | TSHR (0.41) | HSD17B10GLAKDM4ETSHRALOX15 | |
| SCHEMBL6228575 | 0.79 | CYP2C19 (0.43) | ALDH1A1SMN1; SMN2MAPTKMT2AHRH1 | |
| SCHEMBL1968628 | 0.79 | HRH1 (0.33) | HSD17B10GLAKDM4ETSHRALOX15 | |
| SCHEMBL19708433 | 0.78 | ALDH1A1 (0.45) | HSD17B10GLAKDM4ETSHRALOX15 | |
| SCHEMBL31732908 | 0.78 | TDP1 (0.42) | HSD17B10GLAKDM4ETSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473285-B2 | DCN-1 modulating compounds and methods of use thereof | CELLARITY, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-12435087-B2 | Modulators of DCN-1 and methods of use thereof | CELLARITY, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250257063-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-08-14 | — | — | US | disclosed |
| US-20250163058-A1 | MODULATORS OF DCN-1 AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-05-22 | — | — | US | disclosed |
| US-20250163057-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-05-22 | — | — | US | disclosed |
| WO-2025096956-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | CELLARITY, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025096981-A1 | MODULATORS OF DCN-1 AND METHODS OF USE THEREOF | CELLARITY, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| WO-2012125668-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012125668-A1 | TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF | MERCK SHARP & DOHME CORP. (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2010136778-A1 | DIBENZOTHIOPHENE DERIVATIVES AS DNA- PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136778-A1 | DIBENZOTHIOPHENE DERIVATIVES AS DNA- PK INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2010-12-02 | — | — | WO | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12473285-B2 | DCN-1 modulating compounds and methods of use thereof | DCUN1D1, DCUN1D2, DCUN1D4 | HSD17B10 2353/4885GLA 4748/4885KDM4E 4212/4885 |
| US-20250163057-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | DCUN1D1, DCUN1D2, DCUN1D4 | HSD17B10 2353/4885GLA 4748/4885KDM4E 4212/4885 |
| US-20250163058-A1 | MODULATORS OF DCN-1 AND METHODS OF USE THEREOF | DCUN1D1, DCUN1D2, DCUN1D4 | HSD17B10 2578/4885GLA 4619/4885KDM4E 4324/4885 |
| US-20250257063-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | DCUN1D1, DCUN1D2, DCUN1D4 | HSD17B10 2353/4885GLA 4748/4885KDM4E 4212/4885 |
| US-12435087-B2 | Modulators of DCN-1 and methods of use thereof | DCUN1D1, DCUN1D2, DCUN1D4 | HSD17B10 2578/4885GLA 4619/4885KDM4E 4324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.